Critical Illness, Oliguria
Conditions
Brief summary
Acute kidney injury (AKI) is a common disorder and associated with high morbidity and mortality. However, distinguishing transient AKI from persistent AKI may help in individualizing treatment and limit short and long term consequences of AKI. Previous studies suggested usual urinary indices to perform poorly for separating transient from persistent AKI in an unselected population of critically ill patients. The recent KDIGO (Kidney Disease Improving Global Outcomes) guidelines underlined the need for additional strategies in estimating renal short term prognosis. Recently, a Furosemide stress test (FST) was validated in a cohort of unselected critically ill patients. This stress test performance was found to be good in predicting capacity to identify those patients that will progress to advanced stage AKI. Additionally, FST performance was higher than those of usual renal biomarker. The limited sample size of this preliminary study however precluded adjustment for usual confounders including oliguria. The primary objective of this study is to assess diagnostic performance of FST in differentiating transient and persistent AKI. Secondary objectives are to assess diagnostic performance of FST in predicting need for renal replacement therapy, and to confirm FST results after adjustment for confounders.
Interventions
DRUGFurosemide
1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (age \> 18 y.o) * AKI stage 1 or more according to KDIGO * Oliguria as defined by an oliguria lower than 0.5 mL/Kg * Affiliation to the National Medical Insurance
Exclusion criteria
* Pregnancy * Chronic kidney disease stage 4 or more * Need for fluid bolus (\>1000 mL crystalloids or equivalent) or need for vasopressors increases or introduction in the 2 hours preceding inclusion * Evidence of obstructive renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with renal recovery | day 3 |
Secondary
| Measure | Time frame |
|---|---|
| natriuresis(mmol/L) | day 0 to day 3 |
| fractional excretion of sodium(%) | day 0 to day 3 |
| fractional excretion of urea (%), | day 0 to day 3 |
| U/P urea ratio(mg.dl-1/ mg.dl-1) | day 0 to day 3 |
| U/P creatinine ratio (mg.dl-1/ mg.dl-1) | day 0 to day 3 |
Countries
France
Outcome results
None listed